<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00257465</url>
  </required_header>
  <id_info>
    <org_study_id>A/100/0401</org_study_id>
    <nct_id>NCT00257465</nct_id>
  </id_info>
  <brief_title>Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma</brief_title>
  <official_title>M-Vax: A Feasibility and Bio-Equivalence Study Using a DNP-Modified Autologous Melanoma Tumor Cell Vaccine as Therapy in Patients With Stage III or IV Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AVAX Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AVAX Technologies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a vaccine composed of patients' own
      melanoma cells treated with the chemical, dinitrophenyl (DNP)(called a hapten), is safe and
      stimulates an immune response to patients' own cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with stage III or IV melanoma need to have at least one tumor mass of at least 2.5
      cm (about 1 inch) diameter than can be removed for vaccine production. If the vaccine is
      successfully made and if the patient is eligible, the patient will be assigned to receive one
      of 4 doses of the vaccine, include one group that will receive a zero dose. All patients will
      receive injections of their vaccine as part of immune system testing and will receive low
      dose cyclophosphamide and BCG. Eight injections of the vaccine will be administered as an
      injection into the skin of the arm over a 6 month period. Before and after vaccine
      administration, patients will be tested for immunity to their own melanoma cells by DTH
      testing, which is similar to a tuberculosis test. All side effects caused by the vaccine will
      be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immune response to patients' own melanoma cells</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>'Autologous, DNP-modified vaccine (M-Vax)'</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous, DNP-Modified Vaccine (MVax)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous, DNP-Modified Vaccine (MVax)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0 cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous, DNP-modified vaccine (M-Vax)</intervention_name>
    <description>5.0, 2.5, 0.5, or 0 cells</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous, DNP-Modified Melanoma Vaccine</intervention_name>
    <description>5 million cells</description>
    <arm_group_label>A</arm_group_label>
    <other_name>MVax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous, DNP-Modified Vaccine</intervention_name>
    <description>2.5 million cells</description>
    <arm_group_label>B</arm_group_label>
    <other_name>MVax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous, DNP-Modified Vaccine</intervention_name>
    <description>0.5 million cells</description>
    <arm_group_label>C</arm_group_label>
    <other_name>MVax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous, DNP-Modified Vaccine</intervention_name>
    <description>0 cells</description>
    <arm_group_label>D</arm_group_label>
    <other_name>MVax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  stage III or IV melanoma at least one tumor mass of at least 2.5 cm diameter that can
             be excised to make vaccine good performance status

        Exclusion Criteria:

          -  brain metastases need for steroids or other immunosuppressive drugs positive PPD tests
             positive test for HIV, hepatitis B (antigen), or hepatitis C other serious medical
             illnesses
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Berd, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AVAX Technologies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Oncology and Hematology Associates</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol. 2004 Feb 1;22(3):403-15. Epub 2003 Dec 22.</citation>
    <PMID>14691123</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2005</study_first_submitted>
  <study_first_submitted_qc>November 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2005</study_first_posted>
  <last_update_submitted>December 2, 2015</last_update_submitted>
  <last_update_submitted_qc>December 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>melanoma</keyword>
  <keyword>metastatic</keyword>
  <keyword>vaccine</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>autologous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

